Molly M. Hood

1.2k total citations
19 papers, 421 citations indexed

About

Molly M. Hood is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Molly M. Hood has authored 19 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Hematology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Molly M. Hood's work include Cancer Mechanisms and Therapy (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Musculoskeletal synovial abnormalities and treatments (2 papers). Molly M. Hood is often cited by papers focused on Cancer Mechanisms and Therapy (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Musculoskeletal synovial abnormalities and treatments (2 papers). Molly M. Hood collaborates with scholars based in United States, China and Switzerland. Molly M. Hood's co-authors include Jun Du, Juntao Kan, Liang Chen, Chun Hu, Lu Zhang, Scott Wise, Bryan D. Smith, Michael D. Kaufman, Daniel L. Flynn and Cynthia B. Leary and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Nutrients.

In The Last Decade

Molly M. Hood

16 papers receiving 405 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Molly M. Hood United States	9	128	81	78	65	62	19	421
Nannan Liu China	15	267 2.1×	43 0.5×	64 0.8×	35 0.5×	37 0.6×	48	656
Jiyoung Lee South Korea	10	140 1.1×	58 0.7×	35 0.4×	37 0.6×	22 0.4×	24	696
Entezar Mehrabi Nasab Iran	10	127 1.0×	123 1.5×	43 0.6×	19 0.3×	22 0.4×	36	460
Yu-An Hsu Taiwan	14	202 1.6×	140 1.7×	39 0.5×	39 0.6×	43 0.7×	19	677
Lijun Dong China	9	159 1.2×	68 0.8×	25 0.3×	39 0.6×	24 0.4×	18	352
Xiaotian Zhang China	12	166 1.3×	44 0.5×	130 1.7×	40 0.6×	23 0.4×	45	528
Yue Wan China	11	314 2.5×	73 0.9×	49 0.6×	32 0.5×	72 1.2×	22	506
Xiaoran Ma China	14	289 2.3×	49 0.6×	81 1.0×	24 0.4×	36 0.6×	36	541
Bing Dai China	9	293 2.3×	83 1.0×	152 1.9×	27 0.4×	31 0.5×	15	557

Countries citing papers authored by Molly M. Hood

Since Specialization

Citations

This map shows the geographic impact of Molly M. Hood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molly M. Hood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molly M. Hood more than expected).

Fields of papers citing papers by Molly M. Hood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Molly M. Hood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Molly M. Hood. The network helps show where Molly M. Hood may publish in the future.

Co-authorship network of co-authors of Molly M. Hood

This figure shows the co-authorship network connecting the top 25 collaborators of Molly M. Hood. A scholar is included among the top collaborators of Molly M. Hood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Molly M. Hood. Molly M. Hood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Al-Ani, Gada, Jennifer Zwicker, Shamama Javed, et al.. (2024). 29 (PB017): A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents. European Journal of Cancer. 211. 114557–114557.

Al-Ani, Gada, Stacie L. Bulfer, Molly M. Hood, et al.. (2024). Abstract 593: DCC-3084, a brain penetrant RAF dimer inhibitor, broadly inhibits BRAF class I, II, and III alterations leading to growth inhibition of intracranially implanted tumors in preclinical models. Cancer Research. 84(6_Supplement). 593–593.

Al-Ani, Gada, Yu Mi Ahn, Stacie L. Bulfer, et al.. (2023). Abstract 4938: DP-9024, an investigational small molecule modulator of the integrated stress response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors. Cancer Research. 83(7_Supplement). 4938–4938.

Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorganic & Medicinal Chemistry Letters. 74. 128928–128928. 19 indexed citations

Caldwell, Timothy M., Michael D. Kaufman, Scott Wise, et al.. (2022). Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 74. 128929–128929. 7 indexed citations

Caldwell, Timothy M., Yu Mi Ahn, Stacie L. Bulfer, et al.. (2022). Discovery of Vimseltinib (DCC-3014), a Highly Selective CSF1R Switch-Control Kinase Inhibitor, In Clinical Development for the Treatment of Tenosynovial Giant Cell Tumor (TGCT). SSRN Electronic Journal. 2 indexed citations

Hood, Molly M., et al.. (2020). Collagen and soy peptides attenuate contractile loss from UVA damage and enhance the antioxidant capacity of dermal fibroblasts. Journal of Cosmetic Dermatology. 20(7). 2277–2286. 5 indexed citations

Chen, Liang, Chun Hu, Molly M. Hood, et al.. (2020). A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis. Nutrients. 12(4). 1193–1193. 108 indexed citations

Chen, Liang, Chun Hu, Molly M. Hood, et al.. (2020). An Integrated Approach Exploring the Synergistic Mechanism of Herbal Pairs in a Botanical Dietary Supplement: A Case Study of a Liver Protection Health Food. International Journal of Genomics. 2020. 1–14. 13 indexed citations

10.

Kan, Juntao, Junrui Cheng, Leiming Xu, et al.. (2019). The combination of wheat peptides and fucoidan protects against chronic superficial gastritis and alters gut microbiota: a double-blinded, placebo-controlled study. European Journal of Nutrition. 59(4). 1655–1666. 42 indexed citations

11.

Rebhun, John F., Molly M. Hood, Jeffrey D. Scholten, et al.. (2018). Evaluation of selected traditional Chinese medical extracts for bone mineral density maintenance: A mechanistic study. Journal of Traditional and Complementary Medicine. 9(3). 227–235. 4 indexed citations

12.

Harney, Allison S., George S. Karagiannis, Jeanine Pignatelli, et al.. (2017). The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. Molecular Cancer Therapeutics. 16(11). 2486–2501. 105 indexed citations

13.

Kan, Juntao, et al.. (2017). A Novel Combination of Wheat Peptides and Fucoidan Attenuates Ethanol-Induced Gastric Mucosal Damage through Anti-Oxidant, Anti-Inflammatory, and Pro-Survival Mechanisms. Nutrients. 9(9). 978–978. 57 indexed citations

14.

Flynn, Daniel L., Michael D. Kaufman, Cynthia B. Leary, et al.. (2015). Abstract PR01: Rebastinib, a selective TIE2 kinase inhibitor, decreases TIE2-expressing macrophages, reduces metastasis, and increases survival in murine cancer models. Cancer Research. 75(1_Supplement). PR01–PR01. 1 indexed citations

15.

Smith, Bryan D., Michael D. Kaufman, Cynthia B. Leary, et al.. (2015). Abstract A53: The specific FMS kinase inhibitor, DCC-3014, durably inhibits FMS kinase in vivo and blocks cancer bone invasiveness. Cancer Research. 75(1_Supplement). A53–A53. 2 indexed citations

16.

Smith, Bryan D., Molly M. Hood, Scott Wise, et al.. (2015). Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models. Cancer Research. 75(15_Supplement). 2690–2690. 13 indexed citations

17.

Smith, Bryan D., Molly M. Hood, Michael D. Kaufman, et al.. (2013). Abstract B78: Rebastinib, a small molecule TIE2 kinase inhibitor, prevents primary tumor growth and lung metastasis in the PyMT breast cancer model. Cancer Research. 73(3_Supplement). B78–B78. 2 indexed citations

18.

Ahn, Yu Mi, Michael Clare, Carol L. Ensinger, et al.. (2010). Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic & Medicinal Chemistry Letters. 20(19). 5793–5798. 26 indexed citations

19.

Heinrich, Michael C., Scott Wise, Molly M. Hood, et al.. (2010). In vitro activity of novel KIT/PDGFRA switch pocket kinase inhibitors against mutations associated with drug-resistant GI stromal tumors.. Journal of Clinical Oncology. 28(15_suppl). 10007–10007. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact